Nachrichten zu Avicanna

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Aktie

ISIN: CA05368K1003 WKN: A2PN04 SYM: AVCN Land Flagge CA

Kanada

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,3150

CAD

-5,97 %

-0,0200 CAD

Letzter Kurs 10.10.24 Toronto

Geldkurs

10.10.24

0,3000

CAD

170.500 STK

Briefkurs

10.10.24

0,3150

CAD

3.000 STK

Avicanna Aktie kaufen

Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca 23.09.24 · globenewswire · Avicanna
Avicanna Announces Repayment of Debentures 30.08.24 · globenewswire · Avicanna
Avicanna Announces Closing of Non-Brokered Private Placement 29.08.24 · globenewswire · Avicanna
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology 27.08.24 · globenewswire · Avicanna
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark 15.08.24 · globenewswire · Avicanna
Avicanna Reports Q2 2024 14.08.24 · globenewswire · Avicanna
Avicanna Announces Changes of Auditors 02.08.24 · globenewswire · Avicanna
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore 11.07.24 · globenewswire · Avicanna
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update 10.07.24 · globenewswire · Avicanna
Avicanna General Meeting 19.06.24 · globenewswire · Avicanna
Avicanna Announces USPTO Issuance of Patent SEDDS Technology 19.06.24 · globenewswire · Avicanna
Avicanna to Present at the Life Science Investor Forum June 20th, 2024 18.06.24 · globenewswire · Avicanna

Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca 100 Leser

Avicanna Reports Q2 2024 468 Leser
Avicanna Announces Closing of Non-Brokered Private Placement 336 Leser
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical ... 304 Leser
Avicanna Reports Full Year 2023 Audited Financial Results 292 Leser
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark 220 Leser
Avicanna To Hold Full Year 2023 Earnings Conference Call 220 Leser
Avicanna Announces Repayment of Debentures 212 Leser
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter 204 Leser
Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company 192 Leser
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa 176 Leser